The next focusIR Investor Webinar takes places on 14th May with guest speakers from WS Blue Whale Growth Fund, Taseko Mines, Kavango Resources and CQS Natural Resources fund. Please register here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksHutchmed Share News (HCM)

Share Price Information for Hutchmed (HCM)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 352.00
Bid: 350.00
Ask: 352.00
Change: 14.00 (4.14%)
Spread: 2.00 (0.571%)
Open: 348.00
High: 353.00
Low: 342.00
Prev. Close: 338.00
HCM Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

LONDON BRIEFING: JD Sports backs outlook; Spirent accepts new offer

Thu, 28th Mar 2024 08:08

(Alliance News) - Stocks in London traded higher early on Thursday in the final trading day of a holiday-shortened week, despite some hawkish words from a US central banker.

It is also despite unrevised numbers from the Office for National Statistics confirming the UK entered a technical recession in the fourth quarter of 2024.

"The only thing that investors need is the Federal Reserve rate cut dream to stay alive for the June meeting. And for now, that's the case. Activity on Fed funds futures gives around 64% chance for a June rate cut," said Swissquote Bank analyst Ipek Ozkardeskaya.

"But note that, this probability was around 75% last week and it's coming lower as many investors think that the Fed won't be able to cut the rates with robust growth and bumpy inflation. And indeed, the US latest GDP update is due today and is expected to confirm an above 3% growth for the US economy in the last quarter of last year, down from almost 5% printed a quarter earlier. These levels don’t call for an imminent Fed cut."

In early corporate news, JD Sports said it outperformed the sportswear market in its full-year, with like-for-like sales growing.

Here is what you need to know at the London market open:

----------

MARKETS

----------

FTSE 100: up 0.3% at 7,955.13

----------

Hang Seng: up 1.1% at 16,564.84

Nikkei 225: closed down 1.5% at 40,168.07

S&P/ASX 200: closed up 1.0% at 7,896.90

----------

DJIA: closed up 477.75 points, 1.2%, at 39,760.08

S&P 500: closed up 44.91 points, 0.9%, at 5,248.49

Nasdaq Composite: closed up 83.82 points, 0.5%, to 16,399.52

----------

EUR: down at USD1.0802 (USD1.0823)

GBP: down at USD1.2615 (USD1.2630)

USD: up at JPY151.38 (JPY151.35)

Gold: up at USD2,193.16 per ounce (USD2,190.33)

(Brent): up at USD85.66 a barrel (USD85.41)

(changes since previous London equities close)

----------

ECONOMICS

----------

Thursday's key economic events still to come:

08:55 GMT Germany unemployment

09:00 GMT eurozone money supply

12:30 GMT US GDP

12:30 GMT US initial jobless claims

14:00 GMT US pending home sales

14:00 GMT US Michigan consumer sentiment index

15:00 GMT US Kansas City Fed manufacturing activity

----------

The UK slipped into a technical recession in the fourth quarter of 2023, numbers from the Office for National Statistics confirmed on Thursday. UK gross domestic product slumped 0.3% in the three months to December from a quarter earlier, unchanged from initial ONS numbers provided in February. The UK economy had declined 0.1% quarter-on-quarter in the third-quarter of 2023. It means the UK has entered a technical recession at the end of last year, which is generally defined as two successive quarterly falls in gross domestic product. In output terms for the fourth quarter, the ONS said there were falls in all three main sectors: services down 0.1%, production down 1.1% and construction output down 0.9%. Meanwhile, in expenditure terms, there was a fall in the volume of net trade, household consumption and gross capital formation, according to the ONS, partially offset by an increase in government consumption.

----------

The US Federal Reserve should either scale back or delay its interest rate cuts in response to "disappointing" inflation data, a senior Federal Reserve official said. "In my view, it is appropriate to reduce the overall number of rate cuts or push them further into the future in response to the recent data," Fed Governor Christopher Waller told a conference in New York. "Shorter-term inflation measures are now telling me that progress [in reducing inflation] has slowed and may have stalled. But we will need more data to know that," he added. "I see economic output and the labour market showing continued strength, while progress in reducing inflation has slowed," Waller said. "Because of these signs, I see no rush in taking the step of beginning to ease monetary policy," he continued.

----------

BROKER RATING CHANGES

----------

Jefferies cuts Diploma to 'hold' (buy) - price target 3,950 (3,750) pence

----------

Exane BNP cuts Aviva to 'underperform' ('neutral') - target 420 (445) pence

----------

Exane BNP cuts Legal & General to 'neutral' ('outperform') - target 270 (280) pence

----------

COMPANIES - FTSE 100

----------

Retailer JD Sports said it outperformed the sportswear market in the 53 weeks that ended February 3. It said like-for-like sales rose 4.2% on-year and up 8.4% organically on a constant currency basis, while total sales grew 3.6% to around GBP10.5 billion. It expects pretax profit to be in line with its guided range of GBP915 million to GBP935 million, down from GBP991.4 million a year earlier. "We made good strategic progress, opening 215 new JD stores, and focusing our effort on developing JD and enhancing EPS through taking full control of ISRG and MIG," said Chief Executive Officer Regis Schultz. It outlined its initial financial 2025 profit forecast of GBP900 million to GBP980 million, while saying trading in the new financial year-to-date is in line with its expectations after seven weeks. Schultz continued: "Looking ahead, the current trading environment remains challenging due to less product innovation and elevated promotional activity, especially online. We anticipate trading conditions will improve as we move through the year, helped by a busy sporting summer and softer comparatives with last year."

----------

The UK Competition & Markets Authority decided not to refer the planned acquisition by FTSE 100-listed insurer Aviva of AIG's life-insurance and retirement-services division AIG Life to a phase 2 investigation. The UK competition watchdog said this decision was based on the information currently available and that a further announcement on the decision will be made "as soon as is reasonably practicable". In February, the CMA said it was investigating the deal, saying it could reduce competition in the UK services sector.

----------

COMPANIES - FTSE 250

----------

Automated test and assurance solutions provider Spirent said it agreed to a GBP1.16 billion takeover from Keysight Technologies. Spirent said the offer was superior to Viavi's existing GBP1.01 billion bid. The latest offer rates Spirent at 201.5 pence per share, 199.0p in cash and 2.5p in a special dividend. Spirent Chair Bill Thomas commented: "The board of Spirent is pleased to recommend Keysight's cash offer for Spirent, which is an increase of 15% to the Viavi proposal." Chief Executive Officer Eric Updyke added: "Keysight's offer for Spirent will provide further opportunities for our employees and strengthens our customer offering, given Keysight's technology expertise, capabilities and robust global platform with its breadth and depth of industry-leading solutions."

----------

OTHER COMPANIES

----------

Cancer and immunological diseases treatments developer Hutchmed said its supplemental new drug application for savolitinib has been accepted for review by the China National Medical Products Administration. If accepted, the new label indication for savolitinib will be expanded to include treatment-naive patients, those that have not received any treatment, in China. Savolitinib is a treatment for adult patients with locally advanced or metastatic non-small cell lung cancer. It had previously been granted conditional approval in China. "More than a third of the world's lung cancer patients are in China," Hutchmed noted.

----------

Troubled utility Thames Water has said its shareholders will not be injecting the first GBP500 million of funding that was agreed last summer into the group as industry regulations make its business plan "uninvestible". Thames Water – the UK's biggest water supplier with 15 million households across London and the South East – said the funding plan drawn up last July was subject to conditions, including a business plan that is supported by "appropriate regulatory arrangements". It said the regulations being imposed by industry watchdog Ofwat "make the PR24 plan "uninvestible", and as a result the shareholder support letter from last July "has not been satisfied".

----------

By Greg Rosenvinge, Alliance News senior reporter

Comments and questions to newsroom@alliancenews.com

Copyright 2024 Alliance News Ltd. All Rights Reserved.

More News
15 Nov 2022 11:30

Hutchmed refocuses strategy away from early-stage studies

(Sharecast News) - Hutchmed China updated the market on its strategy on Tuesday, following an "in-depth evaluation" of the business.

Read more
15 Nov 2022 10:52

Hutchmed China to shift strategy toward advanced assets in pipeline

(Alliance News) - Hutchmed (China) Ltd announced on Tuesday it will shift focus towards its most advanced assets from its internal developed pipeline, following an evaluation of the business.

Read more
14 Nov 2022 16:55

LONDON MARKET CLOSE: Europe ends higher but New York struggles

(Alliance News) - European equities surrendered some afternoon gains but made a bright start to the week on Monday, shaking off hawkish noise from the US Federal Reserve, while investors waited with bated breath for the outcome of talks between the leaders of the world's two leading economies.

Read more
14 Nov 2022 14:20

IN BRIEF: Hutchmed sees positive results for gastric cancer drug

Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical company - Reports positive top-line results for its gastric cancer treatment fruquintinib, when combined with paclitaxel. Explains the drug met one of its primary endpoints of statistically significant improvement in progression-free survival during a phase-three study in 703 patients, which the firm says is "clinically meaningful". Fruquintinib also shows a "statistically significant improvement" in secondary endpoints including objective response rate, disease control rate, and improved duration of response, Hutchmed adds. The study looked at patients with advanced gastric or gastroesophageal junction adenocarcinoma, a type of cancer.

Read more
14 Nov 2022 10:27

AIM WINNERS & LOSERS: Hutchmed up on positive results for cancer drug

(Alliance News) - The following stocks are the leading risers and fallers on AIM in London on Monday.

Read more
14 Nov 2022 09:40

Hutchmed reports positive results from recent fruquintinib study

(Sharecast News) - Hutchmed China announced initial results from the 'FRUTIGA' phase 3 study of fruquintinib combined with paclitaxel in 703 Chinese patients with advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma on Monday.

Read more
27 Oct 2022 14:27

IN BRIEF: Hutchmed begins phase II/III trial of fruquintinib

Hutchmed China Ltd - Hong Kong-based biopharmaceutical company - Begins randomised, open-label, active-controlled phase II/III trial of fruquintinib combination with sintilimab in China. The trial will explore the combination as a second-line treatment for locally advanced or metastatic renal cell carcinoma - the most common type of kidney cancer. The first patient in China received the dose on Thursday, it says.

Read more
10 Oct 2022 10:24

Hutchmed begins sovleplenib trial for anaemia treatment in China

(Alliance News) - Hutchmed China Ltd on Monday said it has begun a Phase II/III trial of sovleplenib in adult patients with warm antibody autoimmune haemolytic anaemia in China.

Read more
8 Sep 2022 11:02

Hutchmed posts positive results for CRC cancer treatment

(Alliance News) - Hutchmed China Ltd on Thursday said that its fruquintinib treatment reduced risk of death by 34% in metastatic colorectal cancer patients.

Read more
9 Aug 2022 10:04

Hutchmed notes dosing of first participant in IMG-004 study

(Alliance News) - Hutchmed China Ltd on Tuesday said it has dosed its first participant in its global phase one trial of IMG-004.

Read more
8 Aug 2022 12:42

Hutchmed upbeat on latest study results for colorectal cancer treatment

(Sharecast News) - Hutchmed China announced on Monday that the "pivotal" global phase three trial evaluating the investigational use of 'fruquintinib' met its primary endpoint of overall survival in patients with advanced, refractory metastatic colorectal cancer (CRC).

Read more
8 Aug 2022 11:32

UPDATE: Hutchmed, AstraZeneca move lung cancer drug to phase 3 trial

(Alliance News) - Hutchmed China Ltd and AstraZeneca PLC on Monday said preliminary results from the Savannah phase 2 trial showed a promising objective response rate, and has moved the drug into phase 3 trials.

Read more
8 Aug 2022 09:17

Hutchmed regulatory submission underway as fruquintinib trial succeeds

(Alliance News) - Hutchmed Ltd on Monday announced phase 3 of its fruquintinib FRESCO-2 study met its primary endpoint.

Read more
1 Aug 2022 15:16

TRADING UPDATES: Belvoir, Ingenta revenue up; Symphony revenue down

(Alliance News) - The following is a round-up of updates by London-listed companies, issued on Monday and not separately reported by Alliance News:

Read more
25 Jul 2022 15:59

UK earnings, trading statements calendar - next 7 days

Tuesday 26 July 
Aberforth Smaller Companies Trust PLCHalf Year Results
Ascential PLCHalf Year Results
Bytes Technology Group PLCTrading Statement
Capital & Counties Properties PLCHalf Year Results
Cohort PLCFull Year Results
Compass Group PLCTrading Statement
Dotdigital Group PLCTrading Statement
Drax Group PLCHalf Year Results
easyJet PLCTrading Statement
Ergomed PLCTrading Statement
Franchise Brands PLCHalf Year Results
Games Workshop Group PLCFull Year Results
Gore Street Energy Storage Fund PLCFull Year Results
Greencore Group PLCQ3 Results
John Menzies PLCTrading Statement
Medica Group PLCTrading Statement
Mitie Group PLCTrading Statement
NewRiver REIT PLCTrading Statement
Playtech PLCTrading Statement
Reach PLCHalf Year Results
Ricardo PLCTrading Statement
Sabre Insurance Group PLCHalf Year Results
SME Credit Realisation Fund LtdFull Year Results
Trifast PLCFull Year Results
Tyman PLCHalf Year Results
Unilever PLCHalf Year Results
Vivo Energy PLCHalf Year Results
Wickes Group PLCTrading Statement
Wednesday 27 July 
Aptitude Software Group PLCHalf Year Results
BlackRock Energy & Resources Income Trust PLCHalf Year Results
Breedon Group PLCHalf Year Results
British American Tobacco PLCHalf Year Results
FirstGroup PLCTrading Statement
Fresnillo PLCQ2 Production Results
GSK PLCHalf Year Results
Hargreaves Services PLCFull Year Results
Hiscox LtdTrading Statement
Ibstock PLCHalf Year Results
International Personal Finance PLCHalf Year Results
Lancashire Holdings LtdHalf Year Results
Lloyds Banking Group PLCHalf Year Results
Marston's PLCTrading Statement
Motorpoint Group PLCTrading Statement
musicMagpie PLCHalf Year Results
Nichols PLCHalf Year Results
Primary Health Properties PLCHalf Year Results
Quartix Technologies PLCHalf Year Results
Reckitt Benckiser Group PLCHalf Year Results
Rio Tinto PLCHalf Year Results
Smart Metering Systems PLCHalf Year Results
Smurfit Kappa Group PLCHalf Year Results
Ted Baker PLCTrading Statement
Unite Group PLCHalf Year Results
Wizz Air Holdings PLCQ1 Results
Yourgene Health PLCFull Year Results
Thursday 28 July 
Airtel Africa PLCTrading Statement
Anglo American PLCHalf Year Results
Aveva Group PLCTrading Statement
BAE Systems PLCHalf Year Results
Barclays PLCHalf Year Results
Bodycote PLCHalf Year Results
BT Group PLCQ1 Results
Centrica PLCHalf Year Results
CVS Group PLCTrading Statement
De La Rue PLCTrading Statement
Diageo PLCFull Year Results
discoverIE Group PLCTrading Statement
Dr Martens PLCTrading Statement
Elementis PLCHalf Year Results
FDM Group PLCHalf Year Results
Forterra PLCHalf Year Results
Foxtons Group PLCHalf Year Results
GB Group PLCTrading Statement
Greencoat UK Wind PLCHalf Year Results
Hammerson PLCHalf Year Results
Headlam Group PLCTrading Statement
Inchcape PLCHalf Year Results
Indivior PLCHalf Year Results
Informa PLCHalf Year Results
ITV PLCHalf Year Results
Jupiter Fund Management PLCHalf Year Results
Logistics Development Group PLCTrading Statement
Metro Bank PLCHalf Year Results
Mitchells & Butlers PLCTrading Statement
Mortgage Advice Bureau (Holdings) PLCTrading Statement
Mothercare PLCFull Year Results
MySale Group PLC Trading Statement
National Express Group PLCHalf Year Results
Quixant PLCTrading Statement
Rathbones Group PLCHalf Year Results
Relx PLCHalf Year Results
Rentokil Initial PLCHalf Year Results
Restore PLCHalf Year Results
Robert Walters PLCHalf Year Results
Schroders PLCHalf Year Results
Segro PLCHalf Year Results
Shell PLCHalf Year Results
Smith & Nephew PLCHalf Year Results
St James's Place PLCHalf Year Results
Vesuvius PLCHalf Year Results
Volex PLCHalf Year Results
Weir Group PLCHalf Year Results
Friday 29 July 
Allianz Technology Trust PLCHalf Year Results
Aston Martin Lagonda Global Holdings PLCHalf Year Results
AstraZeneca PLCHalf Year Results
Babcock International Group PLCFull Year Results
CMC Markets PLCTrading Statement
Croda International PLCHalf Year Results
Glencore PLCTrading Statement
IMI PLCHalf Year Results
Impellam Group PLCHalf Year Results
Industrials REIT LtdTrading Statement
International Consolidated Airlines Group SAHalf Year Results
Intertek Group PLCHalf Year Results
Law Debenture Corp PLCHalf Year Results
Morgan Advanced Materials PLCHalf Year Results
NatWest Group PLCHalf Year Results
Premier Miton Global Renewables Trust PLCHalf Year Results
Rightmove PLCHalf Year Results
Shearwater Group PLCFull Year Results
Standard Chartered PLCHalf Year Results
Walker Crips Group PLCFull Year Results
YouGov PLCTrading Statement
Monday 1 August 
Ascential PLCHalf Year Results
Cranswick PLCQ1 Results
Dialight PLCHalf Year Results
GlobalData PLCHalf Year Results
HSBC Holdings PLCHalf Year Results
Hutchmed (China) LtdHalf Year Results
NAHL Group PLCTrading Statement
Pearson PLCHalf Year Results
Spectris PLCHalf Year Results
  
Copyright 2022 Alliance News Limited. All Rights Reserved.

Read more

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.